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1. Introduction 
Vasculitis encompasses a heterogeneous group of disorders characterized by inflammation 
of blood vessels. Inflammation affects vessels of any type and size, and causes a wide range 
of clinical manifestations, depending on the vascular bed involved. The preferential size of 
involved vessels and the targeted tissues determine the clinical presentation and serve as 
key elements for classification (Watts & Scott, 2009). Vasculitis may occur as a primary 
process or may be secondary to an underlying disease such as infection, malignancy or other 
systemic autoimmune or chronic inflammatory diseases. Blood vessel inflammation results 
in abnormal vascular remodelling with the potential of severe clinical consequences. In 
some instances, inflammation leads to intimal hyperplasia resulting in vascular stenoses and 
ischemia of the tributary tissues. In other settings, inflammation causes disruption of the 
vessel wall architecture leading to aneurysm formation and eventual dissection or rupture. 
Aortitis is the term used to define inflammation of one or more layers of the aortic wall and 
may have an infectious or non-infectious origin (Gornik & Creager, 2008). Non-infectious 
aortitis is usually part of the spectrum of vascular involvement occurring in primary large-
vessel vasculitis  including giant-cell arteritis (GCA) of the elderly and Takayasu’s arteritis 
(TAK). Aortitis is a major component of these diseases and may lead to severe complications 
including aortic aneurysm, dissection or stenosis.  
Aortitis may also present as a circumscribed condition named isolated aortitis. This term refers 
to aortitis incidentally found at the time of histopathological examination of aortas obtained 
from necropsy studies or from patients who have undergone surgical repair of aortic 
aneurysm or aortic valve replacement.   Existing studies are retrospective and most patients 
have not been prospectively and systematically evaluated in search for a systemic vasculitis or 
other chronic inflammatory diseases. There is some controversy about whether isolated aortitis 
is a specific condition or represents an incomplete view of a systemic disease. 
Occasionally, aortitis may occur in the setting of other primary systemic vasculitis, 
particularly  antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (Chirinos et 
al., 2004; Lee et al., 2008), and  other autoimmune disorders or chronic inflammatory 
diseases (i.e. sarcoidosis, Crohn’s disease, ankylosing spondylitis, Behçet’s disease, Cogan’s 
disease, and IgG4-related disease) (Domenech et al., 2005; Gluth et al., 2006; Palazzi et al., 
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2010; Stone, 2011; Weiler et al., 2000; Okada  et al., 1997).  The main causes of primary and 
secondary aortitis are summarized in table 1. 
Chronic periaortitis is an additional form of aortic inflammation that encompasses a variety 
of conditions and is characterized by inflammatory involvement of the outer layer of the 
aorta and surrounding tissues.   Chronic periaortitis may occasionally occur in patients with 
small-medium sized vessel vasculitis. 
This chapter will particularly focus on aortic inflammation and its consequences in the 
context of the primary large-vessel vasculitis. 
 
  
NON INFECTIOUS AORTITIS  
 
     Primary vasculitis 
 
 
       Large-vessel vasculitis Giant-cell arteritis
 Takayasu’s arteritis
 
       Other vasculitis Granulomatosis with polyangiitis (Wegener’s ) 
 Microscopic polyangiitis
Vasculitis associated  with 
chronic inflammatory or 
autoimmune conditions
 
      Rheumatoid arthritis
 
Sarcoidosis
Systemic lupus erythematosus 
 Behçet disease 
 Cogan syndrome 
 HLA-B27 associated spondyloarthropaties 
 Crohn’s disease 
 
Relapsing polychondritis 
IgG4-related disease 
 
 
Isolated aortitis 
 
 
       
Chronic periaortitis  
      Retroperitoneal fibrosis 
      Inflammatory abdominal aortic aneurysm  
      Perianeurysmal aortitis 
  
INFECTIOUS AORTITIS  
  
     Bacterial Salmonella spp 
 Staphylococcus spp 
 Streptococcus pneumoniae 
 Treponema pallidum spp 
  
     Mycobacterial  Mycobacterium tuberculosis 
Table 1. Causes of aortic inflammation 
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2. Aortic inflammation in primary systemic vasculitis 
2.1 Vasculitis leading to aortic inflammation 
Primary large-vessel vasculitis encompasses GCA and TAK which represent the most 
common disorders associated with non-infectious aortitis. Although histologically similar, 
GCA and TAK are considered distinct disease entities based on demographic and clinical 
features. While GCA affects aged people and is usually associated with cranial symptoms, 
TAK predominantly affects patients younger than 40 years, primarily involves the aorta and 
its major branches but generally spares the cranial arteries. These features usually allow a clear 
clinical differentiation between these two vasculitides. However the increasing  recognition of  
large-artery involvement in GCA during the  past decade widens the overlap features  
between both entities and some authors suggest that they may be part of the spectrum of a 
single disorder (Maksimowicz-McKinnon & Hoffman, 2009). 
2.1.1 Giant-cell arteritis 
GCA is a systemic vasculitis involving large and medium sized vessels in patients older 
than 50 years. The preferential involvement of the cranial arteries  determines the classical 
symptoms of GCA (headache, jaw claudication, scalp tenderness) and its more frequent 
vaso-occlusive complication (visual loss usually due to anterior ischemic optic neuritis).   
About half of the patients have polymyalgia rheumatica  and the majority have prominent 
systemic symptoms (fever, anemia of chronic disease type, and weight loss)  and elevation 
of acute phase reactants. 
Although early descriptions of GCA identified the cranial arteries as the main target of the 
disease, subsequent reports  indicated more widespread vascular involvement (Hunder, 
2006). First report of aortic involvement was in 1937 (Sproul & Hawthorne, 1937) and 
described post-mortem chronic diffuse inflammation with giant cells in the aorta and iliac 
arteries of  two men without apparent premortem symptoms of vasculitis. Over the 
following years, additional cases were reported (Bonnin & Lander, 1956; Cardell & Hanley, 
1951; Cooke & Cloake, 1946; Heptinstall et al., 1954) confirming the potential of GCA to 
involve large-vessels. 
In 1972 Ostberg (Ostberg, 1972) systematically investigated the aorta and its major branches  
in  necropsies from  13 patients with GCA. Inflammatory involvement of the aorta was 
present in 12 out of the 13 patients (90%). Although the necropsy nature of this survey may 
be biased towards the inclusion of more severe cases, these findings suggest that aortic 
involvement might be frequent in GCA.  
More recently, other authors have investigated the prevalence of aortitis in specimens 
obtained from patients who underwent aortic reconstructive surgery because of aortic 
aneurysm, aortic dissection or aortic valve insufficiency. Table 2 summarizes the main 
findings of these studies (Burke et al., 2008; Gelsomino et al., 2005; Homme et al., 2006; Kerr 
et al., 2000; Liang et al., 2009; Miller et al., 2006; Nesi et al., 2009; Pacini et al., 2008; Rojo-
Leyva et al., 2000). Histopathologic analysis of removed aortic fragments revealed chronic 
inflammation in about 1,7 to 8,7%  of patients subjected to aortic surgery.   Patients with 
aortic inflammation were predominantly women and the age average was 65 years.  Among 
these patients, 5-20% had an underlying chronic inflammatory disease, mainly GCA.  The 
design of these retrospective studies is not aimed to estimate the frequency of aortic 
involvement in GCA but underlines the fact that GCA accounts for a significant proportion 
of complicated inflammatory aortitis. 
In the past decade, the vast development of imaging techniques has facilitated the non-
invasive detection of signs suggestive of aortic inflammation in living individuals in early 
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phases, before the development of clinically relevant aortic complications (Pipitone et al., 
2008) (Figures 1 and 2). In this setting, three prospective studies have been conducted to 
determine the prevalence of aortitis in patients with recent-onset GCA. Blockmans et al. 
performed a systematic 18F-Fluorodeoxyglucose (FDG) Positron Emission Tomography 
(FDG-PET) to  35 newly diagnosed GCA patients and found FDG uptake suggestive of 
active inflammation in both the abdominal and the  thoracic aorta in approximatelly half of 
the patients (Blockmans et al., 2006). Agard et al. studied 22 patients with computed 
tomography angiography (CTA) during the first month after GCA diagnosis. Although 
some of these patients had received treatment at the time of the CTA, the authors 
demonstrated radiological signs of aortitis in 45% of patients in the thoracic aorta and in 
23% in the abdominal aorta. Finally, in a prospective study performed by the authors in 40 
newly diagnosed  GCA patients using CTA, radiologic findings suggesting aortitis were 
detected in 65% of patients, which represents the higher prevalence of aortitis found by 
means of imaging techniques (Cid et al., 2009; Prieto-Gonzalez et al., 2009).  
 
Reference Specimen
NIA
(%) 
Gender 
(M/F) 
Age 
(mean)
LVV
Other 
diagnosis
Isolated
aortitis 
(%)
Treatment
Follow-
up 
(mo) 
New 
aneurysms 
Kerr, 2000 
1069 TA
and AA
19 
(1,7)
7/12 73 
19 
GCA
- - 0 12-48 - 
Rojo-Leyva, 
2000 
383 TA 
681 AA 
52 
(4,3)
17/35 63 
4 
GCA
1 
TAK
1 SLE
1 SS, 1 
IBD 
1 RPF 
1 RF 
1 GPA 
1 PAN
36 (69,2) 11 GC 1-144 
6 
(untreated) 
Gelsomino, 
2005 
386 TA 
and aortic 
valve
NA 1/9 74 
10 
GCA
- - 2 GC - 
1 AAA 
(untreated) 
Homme & 
Miller, 
2006 
513 TA 
and aortic 
valve 
45 
(8,7)
8/37 64 
14 
GCA
6 
TAK
2 RA 
1 rective 
arthritis 
21 (46,6) 19 GC 35-196 
7 
(3 untreated) 
Burke, 2008 NA 52 16/36 58 
5 
GCA
1 Crohn
1 SLE 
1 SNA
44 (84,6) - - - 
Pacini, 
2008 
788 TA 
38 
(4,8)
14/24 73 
30 
GCA
1 
TAK
1 Behçet 
1 SLE 
5 (0.6) 0 26-125 1 (AAA) 
Nesi, 2009 338 TA 7 (2) 2/5 >65 
7 
GCA
- - - - - 
Pacini, 
2008 
788 TA 
38 
(4,8)
14/24 73 
30 
GCA
1 
TAK
1 Behçet 
1 SLE 
- 0 26-125 1 (AAA) 
AA: abdominal aorta; AAA: abdominal aortic aneurysm; GC: glucocorticoids; GCA: giant-cell arteritis; 
NIA:non- infectious  aortitis; IBD: inflammatory bowel disease; IS: inmunosupressive agents;  
LVV: large-vessel vasculitis; M/F: male/female; mo: months; PAN: polyarteritis nodosa; SLE: systemic 
lupus erythematosus; SNA: seronegative arthritis; SS: systemic sclerosis; RA: rheumatoid arthritis;  
RPF: retroperitoneal fibrosis; RF: rheumatic fever; TA: thoracic aorta;TAK: Takayasu’s arteritis;  
GPA: granulomatosis with polyangiits (Wegener’s), NA: no available information. 
Table 2. Prevalence of aortitis and associated diseases in surgical specimens. 
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Fig. 1. Cross-sectional view of a CT angiography of a patient with newly diagnosed GCA 
displaying a marked circumferential thickening of the aortic wall.  
 
 
Fig. 2. 18F-FDG-PET scan of a patient with GCA prior to corticosteroid treatment.  
(A) Markedly abnormal uptake of 18F-FDG in the ascending thoracic aorta and carotid 
arteries. (B) Increased 18F-FDG uptake in the aortic arch, abdominal aorta, iliac, subclavian 
and axillary arteries.  
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2.1.2 Takayasu’s arteritis 
TAK is a rare chronic inflammatory granulomatous disease of unknown aetiology that 
affects predominantly young women. It has a worldwide distribution but higher prevalence 
has been reported among Asian populations. TAK primarily affects the aorta and its major 
branches. Pulmonary arteries can also be involved (Kerr et al., 1994; Mwipatayi et al., 2005). 
Aortitis may affect either an aortic segment or involve the entire aorta. Although there is 
considerable variability in disease expression between different geographical areas, the 
initial vascular lesion frequently occurs in the middle or proximal segment of the left 
subclavian artery close to the aorta. In Japanese patients, aortitis has been described mostly 
in the ascending aorta and the aortic arch whereas in Indian patients inflammation 
apparently occurs firstly in the abdominal aorta, subsequently extending towards the 
thoracic segments. (Hata et al., 1996). Aortic involvement is very common in TAK. In 
different series of patients with TAK who underwent imaging studies, aortic involvement 
had been detected in more than 70% of cases.  
2.1.3 Isolated aortitis 
Vasculitis limited to the aorta has been found in post-mortem studies or has been 
incidentally diagnosed in specimens obtained from surgical repair of aortic aneurysms. The 
prevalence of isolated aortitis in the general population is unknown due to the subclinical 
course of this entity.   
In a retrospective review of 1204 aortic surgical specimens obtained over a 20-year period at 
the Cleveland Clinic, idiopathic aortitis was found in 52 patients (4.3%) (Rojo-Leyva et al., 
2000). Sixty-nine percent of these patients had no previous history of systemic vasculitis and 
only 31% of patients had prior history of systemic illnesses known to be associated with 
aortitis. Indications for surgery in patients with isolated aortitis consisted of manifestations 
related to aortic aneurysm (large aneurysm size or progressive enlargement, aortic 
dissection, or aortic valve dysfunction), or coronary artery disease and only in 1 patient 
aortitis was detected at the time of thymoma ressection. In 96% of patients with aneurysm 
formation and idiopathic aortitis, the disease was only identified within the thoracic aorta 
whereas aortic aneurysms not associated with idiopathic aortitis occurred predominantly in 
the abdominal aorta (67%).  
In another recent retrospective study, noninfectious aortitis was detected in 64 patients of a 
series of 766 patients with ascending thoracic aneurysm who underwent surgical repair, 
representing 8.4% of the series. The majority of patients were asymptomatic or had 
aneurysm-related symptoms only, being aneurysm incidentally discovered in a chest x-ray 
or echocardiography. The majority of aortitis (81.3%) were of the isolated variant, with no 
history of chronic inflammatory diseases. Among the remaining, GCA was the entity more 
frequently associated with aortitis.  Eighty-nine percent of patients with noninfectious 
aortitis (57/64) underwent vascular imaging, and additional vascular abnormalities were 
present in 72% of them. Additional imaging findings included stenoses and/or ectasia of the 
major aortic branches (42.1%), descending thoracic aneurysm (31.6%), descending thoracic 
and abdominal aneurysms (21.1%), and abdominal aneurysms (7%). The median follow up 
in this study was 15.4 months, which was insufficient to determine the outcome of these 
additional vascular abnormalities (Liang et al., 2009). Data from these and other surgical 
series are summarized in table 2.    
Therefore, in the majority but not all patients with apparently isolated aortitis, a more 
widespread involvement  indicating systemic large-vessel vasculitis or an associated 
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condition can be detected. Existing studies assessing potentially associated diseases in these 
patients are retrospective and almost certainly underestimate the prevalence of pre-existing 
conditions because many patients with incidentally discovered aortitis had not been 
systematically subjected to an extensive clinical evaluation or imaging study. 
2.1.4 ANCA-associated vasculitis 
Large-vessel involvement and associated complications such as aortic stenoses, aneurysm, 
or dissection have been occasionally reported in patients with small-medium sized vessels 
such as ANCA- associated vasculitis, particularly granulomatosis with polyangiitis 
(Wegener’s) (GPA).  Reported cases,  have well-sustained diagnosis and have no 
epidemiologic, clinical or histopathologic features of GCA or TAK  that might suggest 
misclassification (Chirinos et al., 2004). These findings suggest that aortitis may be part of 
the spectrum of vascular involvement in ANCA-associated vasculitis.  
2.1.5 Chronic periaortitis 
Chronic periaortitis includes several modalities of aortic inflammatory involvement 
including retroperitoneal fibrosis, inflammatory aortic aneurysm and perianeurysmal 
retroperitoneal fibrosis. The last two conditions convey aortic dilatation.   The abdominal 
aorta is most frequently involved. Retroperitoneal fibrosis is idiopathic in most cases but 
may occur in the context of small and medium sized vessel vasculitis, particularly GPA.  
It has also been described in association with microscopic poliangiitis and its renal limited 
variant, and hepatitis C virus-associated cryoglobulinemia. Idiopathic retroperitoneal 
fibrosis may accompany other autoimmune diseases such as rheumatoid arthritis, 
systemic lupus erythematosus, autoimmune thyroiditis) or may be part of other fibrosing 
disorders including orbital pseudotumor, mediastinal fibrosis, sclerosing cholangitis,  
and Riedel’s thyroiditis.  Histopathologically there is a marked aortic adventitial 
inflammation with inflammatory involvement of vasa vasorum extending towards the 
retroperitoneal small vessels and retroperitoneum itself. Inflammatory changes are 
thought to trigger a fibrotic response of variable intensity (Vaglio et al., 2003; Levine et al., 
2006). 
2.2 Clinical manifestations derived from aortitis 
Aortic inflammation is usually asymptomatic until complications derived from 
inflammation -induced vascular remodelling occur. Clinical manifestations are dominated 
by other components of the associated disease.  In patients with GCA cranial, systemic and 
polymyalgic symptoms dominate the clinical picture.  TAK disease is usually more silent 
and indolent and initial manifestations are frequently derived from involvement of the 
aortic branches (vascular bruits, weak or absent pulses, limb claudication, hypertension, 
dizziness or light-headedness) (Kerr GS  et al., 1994;  Macsimowicz-Mckinnon et al., 2007). 
Aortitis  may contribute to the inflammation-associated  non-specific  signs and symptoms 
such as fever, anemia, weigh loss or malaise highly frequent in GCA and also present in  a 
substantial proportion of TAK patients. Complications derived from aortitis  are usually 
manifest and patients may present with severe symptoms related to aortic aneurysm 
enlargement or rupture (i.e. chest pain, abdominal pain, back pain) or aortic valve 
insufficiency (i.e. dyspnea and heart failure,) (Garcia-Martinez et al., 2008; Nuenninghoff et 
al., 2003a; Nuenninghoff et al., 2003b). 
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2.3 Histopathological features 
Aortitis is characterized by patchy areas of medial necrosis and focal loss of medial smooth 
muscle cells, along with adjacent infiltration of lymphocytes, plasma cells, and histiocytes. 
Multinucleated giant cells, if present, are generally found at the borders of necrotic zones. 
The aorta of TAK patients may show thickening of the aortic wall with fibrotic rindlike 
adventitia, and intense medial and adventitial inflammation with granulomas.  It can be 
indistinghishable from aortitis found in GCA. In general, histological features of non-
infectious aortitis are similar and there are no specific features helpful in distinguishing   
isolated aortitis from GCA or TAK (Kerr et al., 2000; Miller et al., 2006; Gravanis, 2000; Hall 
et al., 1985; miller et al., 2006).  
2.4 Diagnosis and assessment of aortic inflammation 
In GCA, diagnosis is usually obtained by temporal artery biopsy. The detection of aortitis 
may have diagnostic usefulness in patients with suspected GCA when temporal artery 
biopsy is not informative or is unavailable. In TAK, the diagnosis is largely based on the 
combination of clinical information, laboratory evaluation, and diagnostic imaging 
(Mukhtyar et al., 2009). Imaging is an essential tool for the diagnosis of TAK because the 
involved vessels are not routinely available for histopathologic examination and in both 
conditions imaging techniques play a critical role in evidencing aortitis.  Among imaging 
modalities, percutaneous intravascular angiography has been traditionally the gold 
standard investigation for the diagnosis of TAK, providing high-quality images of the 
arterial lumen frequently altered in involved vessels. Typical lesions appear as long, 
smooth, tapered stenoses or sometimes complete occlusions intermingled with areas of 
dilatation. Collateral circulation is often prominent because of the slow progression of the 
disease. Modern non-invasive diagnostic modalities including ultrasonography,  PET-scan, 
computed tomography scanning and magnetic resonance angiography have progressively 
replaced conventional angiography for diagnosis of large vessel involvement  because of 
their reduced risks and the ability to provide information not only about the lumen but also 
about the vessel wall. Specific MRI sequences such as delayed contrast-enhanced MRI may 
allow the detection of edema and arterial wall thickening at a reversible stage, prior to the 
development of luminal stenosis.  MRI/MRA may provide useful information avoiding the 
risks associated with arterial puncture, iodinated contrast load and radiation exposure. 
Currently, conventional angiography is basically used to guide endovascular intervention 
procedures or to combine imaging with the detection of central blood pressure in patients 
with significant limb artery stenoses.  
Systematic evaluation of patients with large-vessel vasculitis with imaging studies such as 
color duplex ultrasonography (US), CTA, FDG-PET, angiography, and magnetic 
resonance imaging (MRI) or MR angiography (MRA) has been performed by several 
investigators (Agard et al., 2008; Andrews et al., 2004; Andrews & Mason, 2007; 
Blockmans et al., 2008; Blockmans et al., 2009; Both et al., 2008; Hautzel et al., 2008; Henes 
et al., 2008; Narvaez et al., 2005; Pipitone et al., 2008; Prieto-Gonzalez et al., 2009; Walter et 
al., 2005; Webb & Al-Nahhas 2006). These techniques offer different but complementary 
information to assess large vessel involvement with relative advantages and 
disadvantages which are summarized in Table 3 (Tso E et al., 2002; Blockmans  et al., 2009; 
Cid et al., 2009; ). 
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Technique Findings Advantages Disadvantges 
Color 
Dupplex US 
Wall thickening 
Hipoechoic halo  
Reduced pulsation 
Stenoses/occlusions 
/dilatations 
Lumen patency assessment 
Inexpensive 
Repeatable 
No radiation 
No IV contrast needed 
Communication with the 
patient during the 
procedure 
Good resolution for 
small arteries 
Not suitable for 
structures below air or 
bone 
MRI/MRA 
Wall thickening 
Contrast enhancement 
Stenosis/occlusions 
/dilatations 
Lumen patency assessment 
No radiation 
Repeatable 
Expensive 
Not suitable for 
patients with 
claustrophhobia 
No feasible with metal 
devices 
Limited resolution for 
small vessels 
Gadolinium contrast 
contraindicated if 
impaired renal function 
CTA 
Wall thickening 
Contrast enhancement 
Stenosis/occlusions 
/dilatations 
Lumen patency assessment 
Rapid and available 
Inexpensive 
Repeatable 
Contraindicated if 
renal insufficiency or 
iodine allergy 
Radiation exposure 
FDG-PET 
FDG uptake by metabolically 
active cells such as 
inflammatory infiltrate  
Repeatable 
Whole body assessment 
Expensive  
Not widely available 
No lumen patency 
assessment 
No resolution for 
vessels < 4 mm  
Setting and results not 
standardized 
Requires normal blood 
glucose concentration  
Not suitable for cranial 
arteries due to strong 
cerebral uptake 
Angiography 
Lumen patency assessment 
(smooth, long and tapered 
stenoses or occlusions) 
Therapeutic procedures 
(angioplasty and/or 
stent placement) 
High resolution for small 
vessels 
Central blood pressure 
detection 
Invasive 
Radiation  
Contraindicated if 
renal insufficiency or 
iodine allergy  
No information about 
the vessel wall 
Table 3. Imaging techniques applied to assess large-vessel vasculitis  
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3. Aortic complications in patients with large-vessel vasculitis  
Aortitis may eventually lead to aortic complications in patients with large-vessel vasculitis.  
After the initial inflammatory injury, abnormal vascular remodelling may eventually cause 
aortic structural damage and clinical complications such as aortic aneurysm, dissection, or 
aortic valve insufficiency secondary to aortic root dilatation (Salvarani et al., 2008). Patients 
with GCA tend to develop complications derived from aortic dilatation or dissection 
whereas patients with TAK more commonly develop aortic stenosis but may also develop 
dilatation of the ascending aorta and aortic valve insufficiency.  
3.1 Aortic complications in patients with GCA  
GCA patients are at an increased risk of developing aortic complications. In a retrospective 
population-based study, GCA patients were 17.3 times more likely to develop thoracic aortic 
aneurysms and 2.4 times more likely to develop abdominal aortic aneurysms during follow-
up than individuals of the same age from the general population (Evans et al., 1995). The 
prevalence of aortic complications during follow-up ranged from 9.5 to 18% in three series 
of patients with GCA (Evans et al., 1995; González-Gay et al., 2004; Nuenninghoff et al., 
2003a). Table 4 summarizes the main results of these studies.  
 
 
Fig. 3. (A) Chest x-ray of a 68 -years old woman at the time of GCA diagnosis. (B) Four years 
later the chest radiograph of the same patient showed mediastinum broadening and aortic 
aneurysm was confirmed by CT-scan.  (C) CT scan of another patient wit GCA 
demonstrating an aneurysm with a maximum diameter of  5 cm at the ascending thoracic 
aorta. (D) Aortic dissection at the ascending aortic segment in a patient with GCA 
presenting with chest pain.  
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Evans 
(n=96) 
Nuenninghoff 
(n=168) 
González-Gay
(n=210) 
García-Martínez 
(n=54) 
Design of the 
study 
Retrospective Retrospective Retrospective 
Prospective cross-
sectional evaluation 
GCA diagnosis 1950-1985 1950-1999 1981-2001 1995-2001 
Follow-up 
8.6 yr  
(1 mo – 28 yr) 
7.6 yr  
(3.9 – 13.5) 
Not recorded 5.4 yr (4-10.5) 
Aortic 
complications 
16 (16.6%) 30 (18%) 20 (9.5%) 12 (22.2%) 
Type of aortic 
complication 
2 TAD at GCA 
diagnosis 
9 TAA 
5 AAA 
18 TAA 
16 AAA 
16 TAA 
6 AAA 
11 thoracic 
dilatation/aneurysm 
1 AAA 
Time of 
complication 
discovery after  
GCA diagnosis 
TAA: 5.75 yr 
(2.5 mo-20 yr) 
AAA: 2.5 yr  
(1.3-7.6) 
TAA: 10.9 yr 
(4.5-13.3) 
TAD: 1.1 yr  
(0.2-2.1) 
AAA: 6.3 yr  
(1.1-13.3) 
AAD: 7.6 yr 
3.2 yr (0-13.5) 5.4 yr (4-10.5) 
Histophatologic 
aortitis 
4 / 6 
5 / 7 in TA 
0 / 1 in AA 
Not recorded 0/2 (*) 
CS treatment 
1 yr  
(< 1 mo-4.2 yr) 
Not recorded Not recorded 
Patients were treated 
uniformly and those 
with ASD were able 
to withdraw CS in a 
shorter period of 
time 
TAA: thoracic aortic aneurysm; TAD: thoracic aortic dissection; AAA: abdominal aortic aneurysm;  
AAD: abdominal aortic dissection; CAD: coronary artery disease; yr: years; mo: months;.  
ASD: aortic structural damage (aneurysm or dilatation) 
(*) Only scattered small infiltrates were observed. 
Table 4. Studies evaluating aortic complications in patients with GCA 
Overall, these studies suggest that aortic aneurysms are late complications, usually detected 
several years after the diagnosis of GCA, even in patients that have achieved sustained 
remission and have been able to withdraw corticosteroid therapy. Only 10% of patients with 
GCA evaluated by CT angiography imaging exhibit slight dilatation of the aortic wall at the 
time of diagnosis (Prieto-Gonzalez et al., 2009). Apparently, aortic dissection may occur in 
earlier phases even in the absence of aortic aneurysmal disease and sometimes represents 
the initial event leading to the diagnosis of GCA. In this setting, aortic dissection may occur 
in patients with active inflammation which is demonstrated by histopathologic examination 
of the aortic specimen obtained after surgical repair or necropsy (Lie, 1995; Nuenninghoff et 
al., 2003a). Although the entire aorta may be involved, aneurysms and dissections 
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preferentially develop in the thoracic segments, mainly the ascending aorta. Although 
survival rates are not decreased in patients with GCA, the development of aortic rupture is a 
catastrophic event that carries high morbidity and mortality (Evans et al., 1995; 
Nuenninghoff et al., 2003a). 
In a prospective cross-sectional analysis of 54 GCA patients who were screened with a 
defined protocol after a median follow-up of 5.4 years (range 4-10.5 years), García-
Martínez A et al  found significant aortic structural damage (aneurysm or dilatation) in 
22% of patients which was higher than the prevalence observed in previous retrospective 
studies (García-Martínez et al., 2008). Almost half of the patients in this cohort were 
candidates to surgical repair because of the size of the aneurysm. The ascending aorta was 
the segment involved in three quarters of patients. Aortic structural damage was 
significantly more frequent in men and was not associated with the presence of traditional 
cardiovascular risk factors. When these patients were re-screened after longer follow-up 
(median 8.8 years, range 8-10.5) additional aortic aneurysms appeared in few additional 
patients who had non-dilated aortas in the initial study and one of them developed aortic 
dissection. Histopathological study of the aorta of this patient did not evidence 
persistence of active aortic inflammation but there was marked loss and disruption of 
elastic lamelae.  
 
 
Fig. 4. Post-mortem aortic specimen obtained from a patient who died from aortic dissection 
9 years after the diagnosis of GCA.  A) Hematoxylin-eosin staining showing absence of 
inflammation. B) Orcein staining of a serial section disclosing extensive disruption of the 
elastic fibres, probably due to the initial injury. 
www.intechopen.com
 
Aortitis and Aortic Aneurysm in Systemic Vasculitis 
 
149 
Persistence of inflammatory infiltrates has been described in some aortic specimens 
obtained from necropsies or from patients with aortic aneurysm that have undergone 
surgery years after the diagnosis of GCA (Evans et al., 1995; Lie, 1995; Nuenninghoff et al., 
2003a; Zehr et al., 2005). As a result of these findings, aortic complications are considered to 
be the result of persistent aortic inflammation and the ensuing weakening of the aortic wall. 
However, in a prospective cross-sectional evaluation, persistence of clinically or analytically 
detectable disease activity was not found to be associated with increased risk of aortic 
structural damage (García-Martínez A et al 2008). Patients with aortic dilatation experienced 
less relapses during follow-up, had lower corticosteroid requirements and exhibited lower 
acute-phase reactants than patients without aortic aneurysm or dilatation. Histopathological 
review of the aortic wall in patients who underwent surgery for aneurysm repair evidenced 
only minimal inflammatory infiltrates but important loss and disruption of elastic lamellae 
even in areas devoid of inflammation, probably as a consequence of the initial injury (Figure 
4). The aneurysmal aortic wall exhibited increased expression of matrix metalloproteinase 
(MMP)-2 but not MMP-9 which suggests ongoing remodelling process more than persistent 
aortic inflammation (García-Martínez et al., 2008). Thus, aortic dilatation develops as a 
consequence of complex and probably multifactorial mechanisms.  On the basis of these 
studies it is likely that aortic inflammation and subsequent maladaptative remodelling 
determine the weakening of the aortic wall, which subjected to mechanical stress, may 
eventually undergo dilatation and aneurysm formation over time. 
The life-threatening nature of the potential complications derived from aortic structural 
damage makes mandatory to subject GCA patients to a continuous surveillance by clinical 
examination and imaging, even patients in long-term sustained remission.  The best cost-
benefit screening procedure has not been established but a reasonable approach would 
include performance of a chest X-ray and abdominal US examination every one or two years 
and echocardiogram if aortic bruits are detected.  
3.2 Aortic complications in patients with Takayasu’s arteritis  
As the disease progresses abnormal vascular remodelling   leads to the combination of 
arterial  stenosis/occlusion with arterial aneurysms. However, while stenotic lesions appear 
in almost all patients with TA only 27% of patients develop arterial aneurysms (Kerr GS  et 
al., 1994).  Symptoms derived from involvement of the aortic branches, usually dominate the 
clinical picture and may combine with symptoms derived form aortic involvement. Patients 
may experience symptoms due to vertebrobasilar insufficiency (vertigo, syncope), upper- 
and lower-extremity claudication, transient ischemic attacks or stroke, coronary heart 
disease, or mesenteric ischemia, among others.  
In the aorta stenoses/occlusions are mainly located at the aortic arch, the descending aorta and 
the abdominal aorta, and aortic aneurysms preferentially develop at the ascending thoracic 
aorta (Kerr et al., 1994; Mwipatayi, 2005). More than 70% of patients develop hypertension, 
mainly of renovascular origin but aortic stenosis leading to atypical aortic coarctation may also 
contribute.  Blood pressure treatment and control may be a serious problem in these patients 
since arm blood pressure measurement may not be accurate. TAK patients may also develop 
aortic dilatation or aneurysm with risk of rupture. Aortic valve incompetence has been 
reported in up to one quarter of patients and is generally due to annular or ascending aortic 
dilatation but also as a result of secondary aortic valve changes such as fibrous thickening, 
retraction, and calcification. Congestive heart failure is present in up to one fourth of patients 
www.intechopen.com
 
Etiology, Pathogenesis and Pathophysiology of Aortic Aneurysms and Aneurysm Rupture 
 
150 
who have TAK and usually occurs as a consequence of uncontrolled hypertension or aortic 
regurgitation (Kerr et al. 1994; Macksimowicz-Mckinnon et al. 2007).  
4. Treatment of aortitis and aortic complications 
Treatment of primary large vessel vasculitis is addressed to eliminate clinical symptoms and 
suppress inflammatory activity wherever it is present, including the aorta and its branches.  
However current therapies are not able to completely abrogate inflammation in most cases 
and are not able to prevent complications derived from inflammation-induced vascular 
remodelling which may need to be addressed with surgery or revascularization procedures. 
High dose glucocorticoids are the mainstay of initial therapy to induce remission in large-
vessel vasculitis which must be combined with immunosuppressive agents in the majority 
of patients with TAK.  
4.1 Giant-cell arteritis 
Prednisone or equivalent is usually given to patients with GCA at 1 mg/Kg/day, up to 60 
mg/day for 1 month with subsequent tapering. Low-dose prednisone is maintained for 2-3 
years until complete discontinuation which is achieved by approximately half of the patients.  
Between 40-60% of patients experience a relapsing course. Methotrexate and azathioprine  
have shown modest corticosteroid sparing effects in clinical trials  (Mahr et al. 2007;  Hoffman 
et al. 2002; Cid et al., 2007) and can be used to reduce glucocorticoid exposure in patients  with 
relapsing outcome or with glucocorticoid-related side effects (Mukhtyar et al., 2009).   A 
randomized clinical trial did not show benefit of infliximab  over placebo in maintaining 
remission in patients with newly-diagnosed GCA (Hoffman et al.,2007). Glucocorticoid 
treatment is usually adjusted according to remission of cranial, systemic or polymyalgic 
symptoms and normalization of acute phase reactants. Response of aortic inflammation has 
not been taken into account because the substantial prevalence of aortitis and its potential 
delayed complications has not been appreciated until very recently.   Imaging techniques may 
have promise in assessing the effect of treatment on large-vessel inflammation but their 
sensitivity and specificity are not fully established and, at present, it is premature to adapt 
therapeutic adjustments to the persistence or resolution of imaging abnormalities. 
Since the discovery that aortitis and aortic complications are frequent in GCA is relatively 
recent, there is no evidence supporting whether the discovery of aortic dilatation may have 
therapeutic implications. It is not clear whether aortic dilatation results from persistent 
subclinical inflammation, previous injury, abnormal remodelling, hemodynamic factors or a 
combination of these.  Surgical aortic repair in GCA patients should be performed according 
to standard current guidelines for the general population with aortic disease and preferably 
in patients in remission (Zehr et al. 2005). Since GCA targets aged people, advanced age or 
co-morbidities may unacceptably increase the risk of elective surgery and convenience of 
surgical repair must be carefully weighted in an individual basis.  Endovascular repair of 
aortic aneurysm may be an interesting option but the experience is limited.  Moreover, most 
of the existing   evidence regarding endovascular repair of aortic aneurysm has been 
obtained from abdominal and thoracic descending aneurysms. Endovascular repair of 
ascending aortic dilatation, common in GCA, is technically more difficult (The United 
Kingdom  EVAR trial investigators, 2010a; The United Kingdom  EVAR trial investigators, 
2010b; Kolvenbach  et al., 2011).   
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4.2 Takayasu  arteritis  
For TAK patients, an initial prednisone dose of 1 mg/Kg/day (max 60 mg/day) maintained 
for 1 month and gradually tapered is recommended. With this treatment, 93% of patients 
achieve disease remission. However, remission is sustained in only 20% of patients.  More 
than 70% of patients need adjuvant therapy and long-term low-dose glucocorticoid is 
frequently required by most patients.   Recommendations about immunosuppressive agents 
are based on open-label studies. Methotrexate, azathioprine and mycophenolate are the 
most frequently used. Open-label studies support the potential usefulness of infliximab for 
refractory patients (Mukhtyar et al., 2009; Molloy et al., 2008)  
TAK is a chronic relapsing disease and flares and anatomic progression of vascular lesions 
occur in the majority of patients during follow-up.  
One of the challenges in TAK is to find better surrogate markers of disease activity and 
ongoing inflammation. Clinical data are often non-specific and acute-phase reactants may be 
unreliable indicators. Previous studies of patients undergoing periodic imaging surveillance 
showed inconsistencies in the relationship between acute-phase reactants and the 
development of new vascular lesions during follow-up. In a review of patients with 
clinically inactive disease, new angiographic changes appeared in 60% of them and surgical 
aortic biopsy specimens revealed histological evidence of persistent inflammatory infiltrates 
in 44% of the samples (Kerr et al., 1994). 
Serial imaging has been used for long in the follow-up of patients with TAK since symptoms 
usually occur when severe disruption of the normal vascular architecture has occurred.   
Serial imaging is very useful in detecting new lesions or changes in the existing ones and 
allows an objective assessment of  disease stability or progression.  MRI angiography may 
reveal early signs of vascular inflammation in patients with TAK and is currently being 
evaluated as a potential tool to assess disease activity and response to treatment in 
prospective clinical studies (Andrews & Mason 2007). However, qualitative changes 
suggestive of active disease versus fibrotic scarring do not always accurately predict 
response to therapy. (Tso et al., 2002) . 
Vascular remodelling and scarring may lead to fixed vascular lesions that will not be 
reversed by pharmacologic therapy. Revascularization or surgical repair should be 
considered if stenotic or occlusive lesions lead to significant haemodynamic effects with 
ischemic symptoms, or if aneurysmal enlargement results in increased risk of rupture, 
dissection or in case of aortic valve regurgitation (Mukhtyar et al., 2009). 
For correction of stenoses and occlusions of the aorta and its branches the largest body of 
experience comes from bypass graft procedures where good long-term outcomes have been 
achieved. On average, a 20 to 30% rate of restenosis or occlusion is reported on long-term 
follow-up. Revascularization can also be achieved by percutaneous transluminal 
angioplasty (PTA). PTA is less invasive than vascular surgery and is currently the 
revascularization procedure of choice. Angioplasty is usually successful but the rate of 
restenosis during follow-up is higher than with vascular surgery. Endovascular angioplasty 
has shown better outcomes for lesions that are short and not already occluded. To prevent 
restenosis, stents are currently used although conventional stents have been associated with 
high rates of failure in long-term follow-up studies. The long-term impact of angioplasty in 
patients with TAK is still uncertain because there have been no reports describing the 
outcome of angioplasty with or without stenting after periods longer than 10 years. 
Encouraging results have been reported with the use of drug-eluting stents in atheromatous 
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vascular disease. Their benefit in the treatment of patients with TAK needs to be determined 
(Liang et al., 2009). 
In patients with hypertension, anatomical correction of lesions such as renal artery or aortic 
stenosis should also be performed. When needed, the most common procedure to repair 
aortic stenosis has been an aortoaortic bypass with the use of a prosthetic graft. Angioplasty 
with or without stenting may also be of use to treat discrete stenosis of the aorta. Aortic 
aneurysm should be repaired according to the current guidelines for general population. 
Aortic valve incompetence with aortic ring expansion may necessitate root and aortic valve 
replacement or valvuloplasty. Complex vascular reconstructions (i.e. complete aortic arch 
replacement) may be need by patients with multiple stenosis. 
Patients with TAK have lower rates of sustained vessel patency for angioplasty and arterial 
bypass procedures than patients undergoing intervention for atherosclerosis or other 
vascular diseases. Failure has been associated with the presence of active disease at the time 
of surgery. Thus, in order to improve the life-span of the revascularized vessel and 
minimize the risk of surgical dehiscence, interventions should ideally be performed during 
inactive disease. However, when an earlier surgical intervention is mandatory it can also be 
successfully accomplished during the acute stage. In this scenario, treatment with steroids 
and/or immunosuppressive agents should be continued after surgery. Some authors 
recommend to carefully select the anastomotic site excluding inflamed vascular areas in 
order to avoid  occlusion of the reconstructed vessel, anastomotic disruption or aneurysm 
development at the site of anastomosis (Ogino et al., 2008). 
Recent advances in immunosuppressive and surgical therapies, including endovascular 
interventions, have improved the outcome of patients with TAK. However, longer follow-
up studies are still necessary to get statistically valid conclusions about the impact of these 
therapies on the natural history of TAK. In addition, patients with TAK may develop 
accelerated atherosclerosis as a consequence of systemic chronic inflammation and long-
term hypertension. Therefore, in order to improve the long-term outcome of these patients, 
a careful control of traditional vascular risk factors is crucial to prevent the potential 
vascular complications associated with atherosclerosis.  
4.3 Isolated aortitis  
Patients with incidentally discovered noninfectious aortitis should be evaluated for 
additional areas of arterial disease and for signs and symptoms of systemic inflammatory 
conditions potentially associated with aortitis. The evaluation should include a full patient 
interview, a complete physical examination with particular focus on the vascular system, 
and appropriate laboratory testing including acute phase reactants. Imaging of the entire 
aorta and its main branches with MRI or CTA to exclude abnormalities in other vascular 
beds should be considered. 
It is not clear at present whether patients with incidentally discovered aortitis in whom a 
systemic vasculitis or systemic disease has been reasonably ruled out should receive therapy 
with glucocorticoids and/or immunosuppressants following resection of the affected aortic 
segment. Data from retrospective studies indicate that the longterm outcome of patients 
with isolated aortitis is generally good.  However, in a retrospective study performed at the 
Cleveland Clinic in which 36 out of the 52 patients with idiopathic aortitis were followed for 
a mean of 3.25 years, 6 out of the 25 patients not receiving therapy after the initial surgery 
developed new aortic aneurysm during follow-up. Conversely, recurrent aneurysms were 
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not identified among 11 corticosteroid-treated patients, in spite that treatment schedule was 
not standardized and some patients received very short courses of corticosteroids (Rojo-
Leyva F., et al 2008). 
Therefore, the decision to treat with glucocorticoids or immunosuppressive agents should 
be individually considered, depending on the clinical presentation and the location and 
extent of inflammation. Patients with idiopathic aortitis require careful and periodic 
surveillance during follow-up because small case series have identified a propensity toward 
aneurysm formation in other vascular beds over time. Prospective follow-up studies of 
patients with isolated aortitis are required to further clarify this point.   
5. Conclusions 
Over the past decade, the improvement and wider use of imaging techniques has motivated 
an increasing appreciation of the relevance of aortic involvement in systemic vasculitis and 
its potential for severe complications.  Persistent aortitis observed in some patients by means 
of imaging or histopathologic examination questions the ability of current therapies to 
completely suppress the inflammatory process in spite of the clinical remission of the initial 
symptoms.  It remains to be determined whether patients with asymptomatic persistent 
signs of aortitis  would benefit  form more intensive therapy since  recent data suggest that 
persistent low-grade subclinical  inflammatory activity is not clearly associated with higher 
frequency of aortic complications.  On the other hand, mechanisms involved in aortic 
dilatation are not completely understood. It is unclear at present whether aortic dilatation 
results from persistent subclinical activity, abnormal vascular remodelling following the 
initial injury, hemodynamic influences or a combination of factors.  The indication and best 
method for elective repair of aortic dilatation or stenosis need to be delimitated. Awareness 
of aortic participation in systemic vasculitis raises a number of important questions and 
opens an exciting research agenda for coming years that will definitely benefit from 
multicenter collaboration 
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